Eldred Rock Partners LLC Has $11.31 Million Stake in Merck & Co., Inc. $MRK

Eldred Rock Partners LLC trimmed its position in Merck & Co., Inc. (NYSE:MRK) by 11.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 107,416 shares of the company’s stock after selling 13,464 shares during the period. Merck & Co., Inc. makes up approximately 2.9% of Eldred Rock Partners LLC’s investment portfolio, making the stock its 19th largest holding. Eldred Rock Partners LLC’s holdings in Merck & Co., Inc. were worth $11,307,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Darwin Wealth Management LLC raised its position in Merck & Co., Inc. by 237.4% in the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after buying an additional 216 shares during the last quarter. Kilter Group LLC acquired a new position in Merck & Co., Inc. during the 2nd quarter worth approximately $27,000. Barnes Dennig Private Wealth Management LLC boosted its position in Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock worth $30,000 after acquiring an additional 266 shares during the last quarter. United Financial Planning Group LLC bought a new position in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $31,000. Finally, Evolution Wealth Management Inc. acquired a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $31,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Down 0.2%

NYSE MRK opened at $120.62 on Friday. The company has a market cap of $298.21 billion, a PE ratio of 16.57, a PEG ratio of 2.44 and a beta of 0.26. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The stock has a 50 day moving average of $117.47 and a 200-day moving average of $102.80.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. During the same period in the previous year, the company earned $1.72 earnings per share. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 46.70%.

Insider Activity at Merck & Co., Inc.

In other news, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total value of $5,023,261.17. Following the sale, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at approximately $10,787,865.12. This represents a 31.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the sale, the chief marketing officer owned 80,615 shares of the company’s stock, valued at $9,825,356.20. This trade represents a 19.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 320,176 shares of company stock worth $38,281,735 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: European approval expands KEYTRUDA use to a platinum‑resistant ovarian cancer population (PD‑L1 CPS ≥1). This label adds a new, high‑need indication and could incrementally lift oncology sales in Europe if uptake is steady; approval reduces regulatory uncertainty for the combo in that market. Merck granted EU approval of Keytruda combo in ovarian cancer
• Positive Sentiment: European Commission press release confirming KEYTRUDA + paclitaxel ± bevacizumab approval for PD‑L1‑positive, platinum‑resistant recurrent ovarian carcinoma — reinforces the commercial significance of the approval and the company’s oncology momentum in EU markets. European Commission Approves KEYTRUDA combo
• Positive Sentiment: Merck reported strong Phase 3 results for an oral PCSK9 candidate (enlicitide decanoate) — if confirmed through regulatory paths, an oral PCSK9 could be a major commercial opportunity in lipid management and compete with injectables, implying material long‑term upside to cardiovascular franchise revenue. Merck Reports Strong Phase 3 Results for Oral PCSK9
• Positive Sentiment: Initiation of a pivotal Phase 2b/3 trial for MK‑8748 (Tiespectus) in neovascular AMD shows Merck advancing a novel bispecific Tie2 agonist/VEGF inhibitor into registrational testing — de‑risks a promising ophthalmology program and could add a new specialty product if successful. Merck Announces Initiation of Pivotal Phase 2b/3 Trial
• Positive Sentiment: Royal Bank of Canada assigned an Outperform rating — analyst upgrades/support can buoy sentiment and buying interest, especially when coupled with pipeline news and recent beats. Merck Earns Outperform Rating from RBC
• Neutral Sentiment: Merck released detailed Phase 2 CADENCE data (WINREVAIR) — more granular data helps investors assess clinical profile and commercial potential, but Phase 2 detail typically moves shares less than registrational results unless outcomes are transformational. Merck Announces Detailed Results From the Phase 2 CADENCE Study
• Neutral Sentiment: Merck completed the acquisition of JSR Life Sciences’ chromatography business — broadens manufacturing/service capabilities (note: some headlines refer to Merck KGaA; confirm scope). Strategic but not immediately revenue‑moving for MRK’s core drug sales. Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business
• Neutral Sentiment: Sector commentary: Lilly warned against locking pricing‑deal rules into law, citing innovation risk — a reminder of policy/regulatory uncertainty that can affect the whole pharma sector, including MRK, but it’s not a company‑specific development. Lilly Pushes Back on Making Drug Price Deals Permanent

Analyst Upgrades and Downgrades

A number of analysts have recently commented on MRK shares. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday. BMO Capital Markets upgraded shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $82.00 to $130.00 in a research note on Thursday, December 18th. Guggenheim boosted their price target on shares of Merck & Co., Inc. from $122.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Weiss Ratings restated a “hold (c)” rating on shares of Merck & Co., Inc. in a research note on Monday, December 29th. Finally, Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $127.13.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.